Arcturus Therapeutics Holdings Inc
$ 6.83
3.64%
04 Dec - close price
- Market Cap 194,058,000 USD
- Current Price $ 6.83
- High / Low $ 6.85 / 6.47
- Stock P/E N/A
- Book Value 8.24
- EPS -2.46
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.27 %
- 52 Week High 24.17
- 52 Week Low 5.85
About
Arcturus Therapeutics Holdings Inc. is a pioneering biopharmaceutical company based in San Diego, California, dedicated to the development of RNA-based therapeutics aimed at addressing critical unmet medical needs, particularly in liver and respiratory diseases. The company leverages its proprietary RNA delivery platform to advance a promising pipeline of innovative drug candidates, focusing on enhancing patient outcomes. With a strong emphasis on technological advancements and industry expertise, Arcturus is strategically positioned to capitalize on emerging opportunities in the biotechnology sector, making a significant impact on the future of healthcare.
Analyst Target Price
$35.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-04 | 2025-06-13 | 2025-03-05 | 2024-11-07 | 2024-08-05 | 2024-05-08 | 2024-03-07 | 2023-11-14 | 2023-08-07 | 2023-05-09 | 2023-03-28 |
| Reported EPS | -0.49 | -0.34 | -0.52 | -1.11 | -0.26 | -0.64 | -1 | -0.32 | -0.61 | -1.98 | 1.87 | 4.43 |
| Estimated EPS | 5.53 | 3.21 | -1.19 | -0.4943 | -1.22 | -1.6 | -1.19 | -0.99 | -1.69 | -0.21 | 0.06 | 0.98 |
| Surprise | -6.02 | -3.55 | 0.67 | -0.6157 | 0.96 | 0.96 | 0.19 | 0.67 | 1.08 | -1.77 | 1.81 | 3.45 |
| Surprise Percentage | -108.8608% | -110.5919% | 56.3025% | -124.56% | 78.6885% | 60% | 15.9664% | 67.6768% | 63.9053% | -842.8571% | 3016.6667% | 352.0408% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 4.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARCT
2025-03-09 00:00:00
Following its latest yearly report, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has seen analysts significantly lower their expectations for 2025. Revenues came in 13% below expectations, and statutory losses ballooned, leading to a serious cut in future revenue outlook and increased loss per share forecasts. Despite the weaker earnings outlook, the average price target remained largely unchanged, though a wide range of estimates highlights diverging analyst opinions.
2024-11-14 13:44:00
Arcturus Therapeutics is continuing to evaluate LUNAR-CF [ARCT-032] for Cystic Fibrosis, with interim phase 2 results expected in the first half of 2025. The company also anticipates interim results for LUNAR-OTC in the same timeframe and a CHMP opinion on KOSATIVE for COVID-19 by December 2025. Arcturus has already earned significant milestone payments from CSL.
2024-11-12 00:00:00
The FDA has approved a Phase 1 clinical trial for a self-amplifying mRNA vaccine candidate (ARCT-2304) developed by Arcturus Therapeutics Holdings Inc. for H5N1 avian influenza. Funded by the Biomedical Advanced Research and Development Authority, the trial will assess the vaccine's safety, reactogenicity, and immunogenicity in approximately 200 healthy adults. This innovative mRNA technology aims to provide quicker production and lower dosing compared to traditional vaccine methods, enhancing pandemic preparedness.
2024-09-13 08:15:00
Japan's Ministry of Health, Labor and Welfare (MHLW) has approved CSL and Arcturus Therapeutics' updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®, designed to protect against the JN.1 lineage of Omicron subvariants. Meiji Seika Pharma, CSL's exclusive partner in Japan, will begin distributing the vaccine for the October COVID-19 vaccination campaign, making it the world's first commercially available sa-mRNA COVID-19 vaccine for adults 18 and older. This approval highlights the commitment of CSL and Arcturus Therapeutics to providing innovative vaccine technology to combat respiratory viral diseases.
2024-06-15 00:00:00
Arcturus Therapeutics Holdings Inc's CFO, Andy Sassine, sold 50,000 shares of the company on June 12, 2024, reducing his holdings to 220,526 shares. This transaction follows a trend of 12 insider sells and zero buys over the past year. Despite the insider sale, the company's shares are currently trading at $32.03, which is significantly undervalued compared to its GF Value of $46.78.
2024-05-29 14:23:00
Arcturus Therapeutics Holdings Inc. has seen a 45% boost in its share price over the last month and 44% over the last year. Despite this recent rise, its Price-to-Sales (P/S) ratio of 8.3x is considered low compared to the biotech industry average, driven by a 56% decline in revenue last year and projected future growth (51% annually) that significantly lags the industry forecast (209% annually). This suggests investors are cautious about its future growth prospects, leading to its depressed P/S ratio.
